MACTER Pharmaceuticals: Major
Health Technology
Mkt Cap
13.4B
P/E (TTM)
16.48
EPS
16.95
ROE
21.95%
Div Yield
1.29%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 10.36B | 7.97B | 6.93B | 5.61B | 5.37B | |
| Cost of Goods Sold | -5.79B | -4.72B | -4.15B | -3.17B | -3.22B | |
| Gross Profit | 4.57B | 3.25B | 2.78B | 2.44B | 2.15B | |
| SG&A Expenses | -3.28B | -2.59B | -2.25B | -1.94B | -1.71B | |
| Research & Development | -65.53M | — | — | — | — | |
| Depreciation | -277.79M | -256.11M | -205.81M | -166.78M | -137.82M | |
| Other Operating Expense | -25.36M | -10.58M | -5.34M | -7.53M | -5.85M | |
| Total Operating Expense | -9.09B | -7.32B | -6.41B | -5.12B | -4.94B | |
| Operating Income (EBIT) | 1.27B | 654.60M | 517.51M | 490.97M | 434.95M | |
| Interest Income | 12.14M | 14.27M | 9.41M | 5.92M | 3.92M | |
| Interest Expense | -133.99M | -110.40M | -72.45M | -44.88M | -139.23M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -3.41M | 34.21M | 47.92M | 18.32M | -732.0K | |
| Total Non-Operating Income | -125.25M | -61.92M | -9.95M | -20.65M | -136.05M | |
| Pre-Tax Income | 1.14B | 592.68M | 507.56M | 470.32M | 298.90M | |
| Income Tax | -354.44M | -190.47M | -158.77M | -184.31M | -83.02M | |
| Minority Interest | -10.50M | 4.49M | 8.34M | 5.81M | 10.09M | |
| Net Income | 776.43M | 406.69M | 357.13M | 291.82M | 225.98M | |
| EBITDA | 1.55B | 914.75M | 727.87M | 662.18M | 578.49M | |
| EPS (Basic) | 16.95 | 8.88 | 7.80 | 6.60 | 5.77 | |
| EPS (Diluted) | 16.95 | 8.88 | 7.80 | 6.60 | 5.77 | |
| Gross Margin | 44.09% | 40.77% | 40.08% | 43.47% | 39.99% | |
| Operating Margin | 12.23% | 8.21% | 7.47% | 8.75% | 8.10% | |
| EBITDA Margin | 14.94% | 11.47% | 10.51% | 11.80% | 10.77% | |
| Pre-Tax Margin | 11.02% | 7.43% | 7.33% | 8.38% | 5.56% | |
| Net Margin | 7.49% | 5.10% | 5.16% | 5.20% | 4.21% |